Novavax Medical Information
DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Canada ONLY.
Information on the
NUVAXOVIDTM XBB.1.5 COVID-19 Vaccine (Recombinant protein, Adjuvanted)
and
Novavax™ COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)
NUVAXOVIDTM XBB.1.5 COVID-19 Vaccine (Recombinant protein, Adjuvanted)
and
Novavax™ COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)
If your enquiry is regarding
NUVAXOVIDTM XBB.1.5 COVID-19 Vaccine (Recombinant protein, Adjuvanted)
or
Novavax™ COVID-19 Vaccine, Adjuvanted (2023-2024 Formula), you can find some useful information in the resources below.
NuvaxovidTM XBB.1.5 COVID-19 Vaccine (Recombinant protein, Adjuvanted)
NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted)
Request Medical Information
Do you have a medical or scientific question about a Novavax medicinal product? Get in touch with Novavax Medical Information experts who will provide tailored, evidence-based, balanced, and up-to-date medical information.
Healthcare Professionals may request medical information via ONE of the following ways:
Option 1: Complete and submit a Medical Information Request Form by clicking on the button below.
Option 2: Call 1 855 239-9172 between 9 h 30 et 21 h 30 HT.
Report an Adverse Event (AE)
If you are concerned about an adverse event, it should be reported to the Health Canada at www.canada.ca.
Alternatively, adverse events of serious concern in association with a Novavax product can be reported at 1 855 239-9172 or https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html.
Product Quality Complaint
If you would like to report a complaint regarding the quality of a product, you can access the Health Canada product complaint form via this link: